Back to fellows
Profile Background

Abraham Alabi

Related fellows

Dr Moses Egesa

Associate Professor Jonathan Peter

Head of Allergy and Clinical Immunology

Dr Moses Egesa

Dr David Kateete


Dr Moses Egesa

Dr Suzanne Staples

Chief Strategy Officer & Principal Investigator

Show more

Current Organisation

Center of Medical Research Lambaréné (CERMEL)

Current Job Title

Senior Biologist



Abraham S. Alabi, Stephen W. Picka, Reubvera Sirleaf, Pacifique R. Ntirenganya, Arnold Ayebare, Nidia Correa, Sarah Anyango, Gerald Ekwen, Emmanuel Agu, Rebecca Cook, John Yarngrorble, Ibrahim Sanoe, Henry Dugulu, Emmanuel Wiefue, Diana Gahn-Smith, Francis N. Kateh, Ezekiel F. Hallie, Christiane G. Sidonie, Aaron O. Aboderin, David Vassellee, Damien Bishop, Daniel Lohmann, Manja Naumann-Hustedt, Alois Dörlemann and Frieder Schaumburg

JAC-Antimicrobial Resistance


Background: Antimicrobial stewardship (AMS) programmes can improve the use of antimicrobial agents. However, there is limited experience in the implementation of such programmes in low- and middle-income countries (LMICs).

Objectives: To assess the effect of AMS measures in south-east Liberia on the quality of antimicrobial use in three regional hospitals.

Methods: A bundle of three measures (local treatment guideline, training and regular AMS ward rounds) was implemented and quality indicators of antimicrobial use (i.e. correct compounds, dosage and duration) were assessed in a case series before and after AMS ward rounds. Primary endpoints were (i) adherence to the local treatment guideline; (ii) completeness of the microbiological diagnostics (according to the treatment guideline); and (iii) clinical outcome. The secondary endpoint was reduction in ceftriaxone use.

Results: The majority of patients had skin and soft tissue infections (n=108) followed by surgical site infections (n=72), pneumonia (n=64), urinary tract infection (n=48) and meningitis (n=18). After the AMS ward rounds, adherence to the local guideline improved for the selection of antimicrobial agents (from 34.5% to 61.0%, P<0.0005), dosage (from 15.2% to 36.5%, P<0.0005) and duration (from 13.2% to 31.0%, P<0.0005). In total, 79.7% of patients (247/310) had samples sent for microbiological analysis. Overall, 92.3% of patients improved on Day 3 (286/310). The proportion of patients receiving ceftriaxone was significantly reduced after the AMS ward rounds from 51.3% to 14.2% (P<0.0005).

Conclusions: AMS measures can improve the quality of antimicrobial use in LMICs. However, long-term engagement is necessary to make AMS programmes in LMICs sustainable.